Aldosterone inhibitor BI 690517 reduced albuminuria when combined with SGLT2 inhibitor

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.
The multinational randomized controlled trial tested the efficacy of BI 690517 to reduce risk hyperkalemia in 586 adults taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
ACE inhibitors and ARBs tend to increase aldosterone levels long-term, while adverse events of aldosterone inhibitors can allow for hyperkalemia, Katherine Tuttle, MD, of the University of Washington School

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart